author-photo

George Wilding

University of Wisconsin-Madison

355

Papers

27428

Citations

Citation Trend

Filter By

Papers (259) Sort By

Journal Conference Others

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center

2018 Journal of Oncology Pharmacy Practice
Show All
- Source
- Cite
- Save
Citations (1)
A Festschrift in Honor of Edward M. Messing, MD, FACS

2018
Show All
- Source
- Cite
- Save
Citations (1)
Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial

2017 Clinical Genitourinary Cancer
Show All
- Source
- Cite
- Save
Citations (1)
A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

2016 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (28)
Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (56)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (624)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

2016 The Lancet
Show All
- Source
- Cite
- Save
Citations (369)